• EMAIL
  • PRINT
  • PDF
  • Bookmark and Share
  • Member, American Board of Trial Advocates

Education

  • J.D., Catholic University of America, Columbus School of Law, 1990
  • B.A., Catholic University of America, magna cum laude, Phi Beta Kappa, 1987

    The Journal of Contemporary Health Law & Policy, Vol. VI, 1990

Bar Admissions

  • New Jersey
  • Florida

Court Admissions

  • U.S. Court of Appeals, Third Circuit
  • U.S. District Court, District of New Jersey
  • U.S. District Court, Southern and Western Districts of New York
  • U.S. District Court, Middle District of Florida

Memberships & Affiliations

Member, American Bar Association

Member, American Board of Trial Advocates (ABOTA)

Member, New Jersey State Bar Association

Member, New Jersey Defense Association

Master, Richard J. Hughes Chapter, American Inns of Court

Wilfred P. Coronato

  • |
Partner
  • T: 973.639.8486
    F: 973.297.3764
    • Four Gateway Center
      100 Mulberry St.
      Newark, NJ 07102

Wilfred P. Coronato is a first-chair trial lawyer. He focuses on civil litigation, with an emphasis on product liability and commercial litigation.

A member of the prestigious American Board of Trial Advocates, Will has extensive experience successfully trying cases and winning appeals in state and federal courts. As lead trial counsel, he recently won a complete jury verdict for Pfizer and Wyeth Pharmaceuticals in a Massachusetts federal court suit over Wyeth’s diet drug Pondimin, which, when used in combination with phentermine, was popularly known as fen-phen. The plaintiff alleged that he developed primary pulmonary hypertension (PPH), an often fatal lung disease, as a result of ingesting Pondimin. The verdict was the first ever defense verdict in a fen-phen PPH case where the jury considered both liability and causation issues simultaneously. Legal Media Group Science Awards named this victory their 2015 Product Liability Impact Case of the Year.

Will also recently tried two cases for Lorillard Tobacco Co., one in Florida state court and the other in Florida federal court.

In addition to his trial and appellate work, Will has managed mass tort litigation in various state and federal courts. He led the national affirmative discovery effort on behalf of a major pharmaceutical company in litigation involving one of the company’s drugs. In doing so, Will developed and implemented efficient procedures relating to the discovery of over 60,000 claimants, saving the client millions of dollars in the process.

Will has also served as New Jersey counsel in pharmaceutical litigations designated pursuant to New Jersey court rules as a “mass tort.”

From January 2000 to July 2002, Will served as Borough Attorney for Fanwood, New Jersey. As Borough Attorney, he was responsible for overseeing the bidding of all contracts for public works, reviewing and negotiating all contracts for professional services and leasing of public property, advising the borough on personnel matters, guiding the mayor and council in their efforts to redevelop the borough's downtown area, and preparing the redevelopment plan pursuant to New Jersey’s Local Redevelopment and Housing Law.

Will also serves on a pro bono basis as the attorney for St. Bartholomew the Apostle Church and St. Bartholomew Academy in Scotch Plains, New Jersey.

Published Decisions

  • Pop Test Cortisol LLC v. Merck & Co. Inc., 2014 WL 1660605 (NJ Super. Ct. App. Div. Apr. 28, 2014) (order compelling arbitration of all claims by the licensee of a cortisol-blocking drug against the licensor affirmed) 

  • Heindel v. Pfizer Inc., 381 F.Supp.2d 364 (D.N.J. 2004) (summary judgment granted to pharmaceutical manufacturers in a putative class action in which plaintiffs claimed they paid inflated prices for prescription drugs due to the concealment of cardiac problems allegedly associated with the drugs) 

  • Doe v. Greater New York Blood Program, 304 NJ Super. 287 (App. Div. 1997) (blood center had no duty in January 1982 to implement high-risk screening procedures or testing for potentially HIV-infected donors)

  • Vitrano v. Schiffman, 305 NJ Super. 572 (App. Div. 1997) (dismissal of physicians affirmed where the plaintiff’s expert was unable to establish causation within medical probability)

Representative Matters

Jury Verdict in favor of Wyeth Pharmaceuticals in a Fen-Phen case alleging failure to warn of primary pulmonary hypertension
Trial on behalf of Lorillard Tobacco Co. in a wrongful death action alleging nicotine addiction resulting in lung cancer, with reversal of the plaintiff’s verdict on a motion for a new trial
Injunctive relief obtained for a client requiring the removal of all defamatory statements from an internet website
Jury Verdict in favor of a defendant gynecologist in a wrongful death action alleging the failure to diagnose gynecological cancer

Speaking

10/20/17
Litigating Public Health Epidemics
American Bar Association, Section of Litigation, Regional CLE Workshop: Current Issues in Pharmaceutical, Medical Device and Biotech Litigation
05/08/14
Evidence Issues Relating to Learned Treatises and Opinions in Medical Records
Trial Attorneys of New Jersey, Evidence and Trial Procedure from the Experts—A Panel Discussion
10/29/08
Developments in New Jersey Litigation of Importance to Drug Manufacturers
Hughes Hubbard Pharmaceutical Conference
08/18/05
Preemption in Medical Device Cases: Lohr and the Regulatory Framework
American Law Institute-American Bar Association, Program on Products Liability: Pharmaceutical and Medical Device Issues

Publications

10/30/17
Parens Patriae Opioid Lawsuits: Should They Be Stayed Pending FDA’s Opioid Action Plan
American Bar Association, Section of Litigation, Regional CLE Workshop: Current Issues in Pharmaceutical, Medical Device and Biotech Litigation Course Materials
07/03/17
03/25/10
01/01/05
The Fracture That Will Not Heal: The Landscape of Federal Preemption in the Fields of Medical Devices, Prescription and Over-The-Counter Drugs Ten Years After Medtronic Inc. v. Lohr
Wilfred P. Coronato, Stephen Lanza
American Law Institute-American Bar Association (ALI-ABA) Course of Study, Products Liability: Pharmaceutical and Medical Device Issues (2005): 365